CD8A and cancer: To further confirm the potential role of Sunitinib in antitumor immunity, we analyzed 14 patients of a phase III trial of metastatic breast cancer treated with Sunitinib combined with docetaxel versus docetaxel alone.[29] We observed a significant increase for IFN‐γ related gene ontology (GO) terms (Figure 1D), CD8A transcript (Figure 1E) and cytolytic activity (CYT),[30] a proxy to reflect the capacity of T cells to kill cancer cells (Figure 1F).